Methods for Adjusting for Bias Due to Crossover in Oncology Trials

No abstract is available for this paper.

• Publication year

  2014

• Venue

  PharmacoEconomics (Auckland)

• Publication date

  2014-03-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40273-014-0145-yPMID 24595585
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.

  2013cited by this paper
• Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

  2011cited by this paper
• NICE guidance on pazopanib for first-line treatment of advanced renal-cell carcinoma.

  2011cited by this paper
• Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma.

  2011cited by this paper
• Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study

  2011cited by this paper
• Limitation of inverse probability-of-censoring weights in estimating survival in the presence of strong selection bias.

  2011cited by this paper
• Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.

  2011cited by this paper
• Phase 3 trial of everolimus for metastatic renal cell carcinoma

  2010cited by this paper
• Performance of statistical methods for analysing survival data in the presence of non‐random compliance

  2010cited by this paper
• Detecting an overall survival benefit that is derived from progression-free survival.

  2009cited by this paper
• Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration Strategies

  2009cited by this paper
• Issues in using progression-free survival when evaluating oncology products.

  2009cited by this paper
• Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure

  2008cited by this paper
• Estimating effects from randomized trials with discontinuations: the need for intent-to-treat design and G-estimation

  2008cited by this paper
• Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issues

  2008cited by this paper
• Analysis of progression‐free survival in oncology trials: some common statistical issues

  2007cited by this paper
• When you look matters: the effect of assessment schedule on progression-free survival.

  2007cited by this paper
• Parametric randomization‐based methods for correcting for treatment changes in the assessment of the causal effect of treatment

  2004cited by this paper
• Walker AS, White IR, Babiker AG

  2004cited by this paper
• A Causal Proportional Hazards Estimator for the Effect of Treatment Actually Received in a Randomized Trial with All‐or‐Nothing Compliance

  2003cited by this paper
• Estimating a treatment effect in survival studies in which patients switch treatment

  2002cited by this paper
• Correcting for Noncompliance and Dependent Censoring in an AIDS Clinical Trial with Inverse Probability of Censoring Weighted (IPCW) Log‐Rank Tests

  2000cited by this paper
• Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men.

  2000cited by this paper
• Survival analyses of randomized clinical trials adjusted for patients who switch treatments.

  1996cited by this paper
• Correcting for non-compliance in randomized trials using rank preserving structural failure time models

  1991cited by this paper
• Regression Models and Life-Tables

  1972cited by this paper
• Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/pds.1064

  year unknowncited by this paper

• Progression-free survival 2 (PFS2) as a surrogate endpoint for overall survival (OS) in breast cancer randomized controlled clinical trials

  2026cites this paper
• Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial.

  2025cites this paper
• Considerations on Interim Evaluation of OS in Pivotal Oncology Trials

  2025cites this paper
• Exploring the characteristics, methods and reporting of systematic reviews with meta-analyses of time-to-event outcomes: a meta-epidemiological study

  2024cites this paper
• A cautionary tale: an evaluation of the performance of treatment switching adjustment methods in a real world case study

  2024cites this paper
• A Unified Three-State Model Framework for Analysis of Treatment Crossover in Survival Trials

  2024influential citation
• Overall survival of patients with CLL treated with ibrutinib in the first line compared to second-line ibrutinib after chemotherapy/chemoimmunotherapy

  2024cites this paper
• Axicabtagene ciloleucel compared to standard of care in Swedish patients with large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial

  2023cites this paper
• Clinical trial considerations for pediatric cancer drug development

  2023cites this paper
• Adjusting for time-varying treatment switches in randomized clinical trials: the danger of extrapolation and how to avoid it

  2023cites this paper
• Meta-epidemiological review identified variable reporting and handling of time-to-event analyses in publications of trials included in meta-analyses of systematic reviews.

  2023cites this paper
• Adjusting for Time-Varying Treatment Switches in Randomized Clinical Trials: The Danger of Extrapolation and How to Address It

  2023cites this paper
• Analysis of sodium phenylbutyrate and taurursodiol survival effect in ALS using external controls

  2023influential citation
• Cross-sectional analysis characterizing the use of rank preserving structural failure time in oncology studies: changes to hazard ratio and frequency of inappropriate use

  2023cites this paper
• Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: Evaluating the impact of treatment crossover on outcomes

  2022cites this paper
• Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

  2022cites this paper
• Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase 3 trial.

  2022cites this paper
• Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China

  2021cites this paper
• The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?

  2021cites this paper
• Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer

  2021cites this paper
• Improved two-stage estimation to adjust for treatment switching in randomised trials: g-estimation to address time-dependent confounding

  2020cites this paper
• Trends in the crossover of patients in phase III oncology clinical trials in the USA

  2020cites this paper
• Economic evaluation of sunitinib versus pazopanib and best supportive care for the treatment of metastatic renal cell carcinoma in Chile: cost-effectiveness analysis and a mixed treatment comparison

  2019cites this paper
• Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis.

  2019cites this paper
• Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring

  2019cites this paper
• Performance of randomization-based causal methods with and without integrating external data sources for adjusting overall survival in case of extensive treatment switches in placebo-controlled randomized oncology phase 3 trials

  2019influential citation
• Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?

  2018cites this paper
• Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study

  2018cites this paper
• Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times?

  2018cites this paper
• The siren song of bevacizumab: swan song or clarion call?

  2018cites this paper
• Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome

  2018cites this paper
• Design and monitoring of survival trials in complex scenarios

  2018cites this paper
• Surrogate study endpoints in the era of cancer immunotherapy.

  2018cites this paper
• Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward.

  2017cites this paper
• Intégration des mesures intermédiaires de survie dans les évaluations économiques en cancer du sein métastatique

  2017cites this paper
• Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.

  2017cites this paper
• Effect of Crossover in Oncology Clinical Trials on Evidence Levels in Early Benefit Assessment in Germany.

  2017cites this paper
• Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia.

  2017cites this paper
• Survival adjusting for crossover: phase 3 study of ibrutinib vs. chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma

  2017cites this paper
• A Multi-State Model for Designing Clinical Trials for Testing Overall Survival Allowing for Crossover after Progression

  2016cites this paper
• Approach to uncertainty in health technology assessment in a Central and Eastern European country: appraisal of cancer drugs by a Polish HTA agency in presence of high crossover rates in clinical trials

  2016cites this paper
• Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review.

  2016cites this paper
• Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.

  2016cites this paper
• The Cost-Effectiveness of Ibrutinib in Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

  2016cites this paper
• Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study

  2016cites this paper
• Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.

  2016cites this paper
• Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review.

  2016cites this paper
• Use of Intermediate Endpoints in the Economic Evaluation of New Treatments for Advanced Cancer and Methods Adopted When Suitable Overall Survival Data are Not Available

  2016cites this paper
• Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer.

  2016cites this paper
• TREATMENT SWITCHING: STATISTICAL AND DECISION-MAKING CHALLENGES AND APPROACHES

  2016cites this paper
• Adjusting for confounding effects of treatment switching in a randomized phase II study of dabrafenib plus trametinib in BRAF V600+ metastatic melanoma

  2015cites this paper
• Treatment switching in oncology trials and the acceptability of adjustment methods

  2015cites this paper
• Bringing in health technology assessment and cost‐effectiveness considerations at an early stage of drug development

  2015cites this paper
• Modelling departure from randomised treatment in randomised controlled trials with survival outcomes

  2014cites this paper
• The role of clinical trials in veterinary oncology.

  2014cites this paper